NCT04446351View on ClinicalTrials.gov

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Neoplasms
Interventions
DRUG

GSK6097608

GSK6097608 will be administered as an IV infusion.

DRUG

Dostarlimab

Dostarlimab will be administered as an IV infusion.

DRUG

Cobolimab

Cobolimab will be administered as an IV infusion.

DRUG

Belrestotug

Belrestotug will be administered as an IV infusion.

Trial Locations (11)

75230

GSK Investigational Site, Dallas

78229

GSK Investigational Site, San Antonio

90025

GSK Investigational Site, Los Angeles

02215

GSK Investigational Site, Boston

77030-4009

GSK Investigational Site, Houston

K1H 8L6

GSK Investigational Site, Ottawa

M5G 1Z5

GSK Investigational Site, Toronto

277-8577

GSK Investigational Site, Chiba

104-0045

GSK Investigational Site, Tokyo

03080

GSK Investigational Site, Seoul

06351

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

23andMe, Inc.

INDUSTRY

collaborator

iTeos Therapeutics

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY